Volunteers Selected For Human Clinical Trial Of Generex Biotechnology Corporation's Synthetic Avian Influenza Vaccine
Published: Feb 05, 2007
TORONTO -- (MARKET WIRE) -- February 05, 2007 -- Generex Biotechnology Corporation (NASDAQ: GNBT) announced today that 50 volunteers have been selected and final preparations made for initiation of human clinical trials of the synthetic avian influenza vaccine under development by its wholly owned subsidiary, Antigen Express, Inc. The Company previously entered into an agreement with the Lebanese-Canadian Hospital in Beirut, Lebanon to conduct the Phase I trial. An additional 70 prospective volunteers are presently being screened by the Hospital. An aggregate of 160 patients are expected to participate in the trial.